Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder.
Despite the well-known association between the hypothalamic-pituitary-adrenal (HPA) axis and normal fear, it is still unclear (a) to what extent corticotropin releasing hormone (CRH) or cortisol itself mediates fear responses, and (b) to what extent the HPA axis also affects panic disorder. The carbon-dioxide (CO2) challenge has been proposed as a model for panic. Participants received the cortisol synthesis inhibitor metyrapone 30 mg/kg of body weight once and placebo once, with 1 week between challenges, at 2300 h. The following morning, blood was taken for cortisol and ACTH levels, and then participants inhaled a single vital capacity inhalation of 35% CO2 and 65% oxygen. Before and after the inhalation, participants completed an inventory of the 13 DSM-IV symptoms of panic and the NIMH questionnaire of psychological and physical symptoms. Eight healthy controls and 14 patients with panic disorder completed the protocol. As expected, CO2 increased measures of anxiety, and metyrapone lowered cortisol and increased ACTH levels. Prechallenge anxiety was modestly lowered by metyrapone, but response to CO2 was not affected. Cortisol and ACTH levels before challenge partly predicted the response to CO2. The results support an anxiogenic role for cortisol in stress, and suggest that the pathophysiological mechanism that mediates CO2-induced panic differs from those underlying other kinds of anxiety.
Belgorodsky
Andrey
A
Division of Psychiatry, Ben Gurion University of the Negev, Beer-sheba, Israel.
Knyazhansky
Leonid
L
Loewenthal
Uri
U
Arbelle
Jonathan
J
Cohen
Hagit
H
Benjamin
Jonathan
J
D000280:Administration, Inhalation; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000963:Antimetabolites / Q000008:administration & dosage / Q000494:pharmacology*; D002245:Carbon Dioxide / Q000008:administration & dosage; D003346:Corticotropin-Releasing Hormone / Q000502:physiology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D006801:Humans; D006854:Hydrocortisone / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism*; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D008797:Metyrapone / Q000008:administration & dosage / Q000494:pharmacology*; D016584:Panic Disorder / Q000175:diagnosis* / Q000503:physiopathology; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011795:Surveys and Questionnaires
D000963:Antimetabolites; D002245:Carbon Dioxide; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D006854:Hydrocortisone; D008797:Metyrapone